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The focal adhesion kinase (FAK) is a mediator of cell-
extracellular matrix signaling events and is overex-
pressed in tumor cells. In order to rapidly down-regu-
late FAK function in normal and transformed mammary
cells, we have used adenoviral gene transduction of the
carboxyl-terminal domain of FAK (FAK-CD). Transduc-
tion of adenovirus containing FAK-CD in breast cancer
cells caused loss of adhesion, degradation of p125FAK,
and induced apoptosis. Furthermore, breast tumor cells
that were viable without matrix attachment also under-
went apoptosis upon interruption of FAK function, dem-
onstrating that FAK is a survival signal in breast tumor
cells even in the absence of matrix signaling. In addi-
tion, both anchorage-dependent and anchorage-inde-
pendent apoptotic signaling required Fas-associated
death domain and caspase-8, suggesting that a death
receptor-mediated apoptotic pathway is involved. Fi-
nally, FAK-CD had no effect on adhesion or viability in
normal mammary cells, despite the loss of tyrosine phos-
phorylation of p125FAK. These results indicate that FAK-
mediated signaling is required for both cell adhesion
and anchorage-independent survival and the disruption
of FAK function involves the Fas-associated death do-
main and caspase-8 apoptotic pathway.
As normal epithelial cells become transformed and develop
the capacity for invasion and metastasis, they must acquire the
property of anchorage-independent growth. This is essential for
tumor cells to survive the apoptotic stimuli associated with the
loss of adhesion, proteolysis, and migration through their ex-
tracellular matrix (ECM)1 (1, 2). Oncogenic transformation has
been shown to suppress apoptosis as a means of enhancing
tumor cell survival (3–6). Cells from human tumors have been
shown to be more resistant to apoptotic stimuli than normal
cells (7). Normal cells undergo apoptosis when they lose ECM
adhesion, and this phenomenon has been termed “anoikis” (8,
9). Tumor cells have been thought to be resistant to anoikis,
thus allowing them to grow in an anchorage-independent fash-
ion. One of the critical signaling molecules involved in both
cell-ECM interactions and anoikis is the focal adhesion kinase
(FAK) (10), a tyrosine kinase that localizes to focal adhesions
(11, 12).
Previous studies have shown that FAK is overexpressed in
breast, colon, and thyroid cancers (13–17), whereas normal
tissues express little detectable FAK. The overexpression of
FAK in tumors is likely to affect three functions as follows:
motility, adhesion, and survival. FAK is thought to play a role
in adhesion-mediated survival because overexpression of a con-
stitutively activated form of FAK in Madin-Darby canine kid-
ney cells has been shown to confer resistance to apoptosis
following loss of adherence (10). FAK overexpression in Chi-
nese hamster ovary (CHO) cells caused an increase in migra-
tion (18), suggesting that FAK may play a role in motility of
CHO cells. Although these experiments were performed in
normal cells, they raise the possibility that tumor cells up-
regulate FAK expression in order to leave their tissue of origin,
invade their surrounding stroma, and migrate into new envi-
ronments. However, FAK overexpression has also been demon-
strated in preinvasive tumors (13), suggesting a role for FAK in
tumors that occurs before development of anchorage-indepen-
dent growth potential.
Earlier work from this laboratory (19) raised the possibility
of an additional function for FAK in tumor cells, that FAK
might act as an inhibitor of apoptosis. Attenuation of FAK
expression by antisense oligonucleotides led to loss of adhesion
and subsequent apoptotic cell death of a variety of tumor cell
types, suggesting that FAK plays a role in tumor cell survival
(19). This resembles the work of Frisch et al. (10), who demon-
strated that an activated form of FAK leads to resistance to
anoikis in the absence of adhesion. Finally, Ilic et al. (20) have
also proposed that FAK acts as a survival signal in murine
FAK-deficient ES cells deprived of ECM attachment.
The carboxyl-terminal domain of FAK (FAK-CD) is analo-
gous to the FRNK molecule (FAK-related non-kinase) that is
expressed as a separate transcript in chick embryo fibroblasts
(21), which is initiated from an alternative promoter within an
intron (22). Avian FRNK decreases phosphorylation of p125FAK
and the protein paxillin and slows the spreading of avian fibro-
blasts (23). Our group has shown (24) that inducible ectopic
FAK-CD expression resulted in decreased p125FAK tyrosine
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phosphorylation, loss of adhesion, and cell death in human
breast cancer cells. However, each of these approaches was
limited by various factors, including the cell type of origin, the
efficiency of gene expression, or the means of inducing FAK-CD
expression. Thus, the mechanisms that are involved in the cell
death by expression of FAK-CD remained largely unknown.
In this report, we have utilized an adenoviral gene transduc-
tion system to interrupt rapidly FAK function, and we demon-
strated that adenoviral transduction of FAK-CD caused loss of
adhesion and apoptotic cell death in tumor cells and corre-
sponded with loss of endogenous p125FAK from focal adhesions.
Apoptosis occurred independently of cell adhesion and ECM
signaling but required FADD, caspase-8, and caspase-3, sug-
gesting an important role of the FAK signaling pathway in
inhibiting death receptor or death receptor-related apoptosis.
In contrast, loss of endogenous p125FAK from the focal adhe-
sions of normal mammary epithelial cells had no effect on
adhesion or viability. Thus, we have shown that FAK has two
distinct functions in tumor cells, promoting adhesion to ECM and
providing survival signals independent of matrix attachment.
EXPERIMENTAL PROCEDURES
Cell Culture—BT474 and MCF-7 human breast carcinoma cells were
purchased from ATCC, and the MCF-10A human mammary epithelial
cells (kindly provided by Dr. Channing Der) were cultured as described
(24–26). Human mammary epithelial cells, isolated from normal hu-
man mammary tissue, were obtained from Clonetics (San Diego, CA)
and maintained in mammary epithelial cell growth medium (Clonetics)
supplemented with 10 ng/ml recombinant human epidermal growth
factor, 5 mg/ml insulin, 0.5 mg/ml hydrocortisone, 50 mg/ml gentamicin,
50 ng/ml amphotericin-B, and 52 mg/ml bovine pituitary extract. 293
human primary embryonal kidney cells were cultured in DMEM con-
taining 10% fetal bovine serum. All of the cell lines were incubated at
37 °C in 5% CO2.
Construction and Preparation of Recombinant Adenoviruses—FAK-
CD, amino acids 693–1052 of FAK fused to the HA epitope tag, was
cloned into the pCRII vector (Invitrogen) as described previously (24).
pCRII-FAK-CD was digested with KpnI and inserted into the KpnI site
of the adenoviral shuttle vector pACCMV.PLPASR(1). We named this
plasmid pACCMV-FAK-CD. Recombinant virus was generated by
transfection of 293 human embryonic kidney cells with 10 mg of pAC-
CMV-FAK-CD and 10 mg of adenovirus type 5 dl309 plasmid (27),
digested with XbaI and ClaI. After transfection, cells were overlaid with
DMEM containing 10% fetal bovine serum and 2% low melt agarose and
then were fed every 3 days. After 11 days, plaques were picked using a
Pasteur pipette and inoculated into 0.5 ml of media. 100 ml of the media
was used to amplify plaques by infecting confluent 293 cells. The
recombinant virus containing FAK-CD, called AdFAK-CD, was con-
firmed by amplifying the FAK-CD-pACCMV junction sequence by po-
lymerase chain reaction and sequencing the polymerase chain reaction
fragment at the University of North Carolina Automated Sequencing
Facility. HA-tagged expression of FAK-CD was also confirmed by West-
ern blot analysis of infected 293 cells using an anti-HA monoclonal
antibody (12CA5, Roche Molecular Biochemicals).
Large amounts of AdFAK-CD were generated by subsequent infec-
tion of 293 cells with AdFAK-CD for 48 h in DMEM containing 2% fetal
bovine serum. Cells were then harvested, resuspended in PBS, and
lysed by freezing and thawing three times. Cell debris was removed by
centrifugation, and the supernatant containing AdFAK-CD was puri-
fied by two cesium chloride density centrifugations (27). The number of
virions per ml was estimated by measuring absorbance at 260 nM (A260),
where an A260 unit is approximately 10
12 virions. Concentrated virus
was dialyzed, aliquoted, and stored at 270 °C. The adenovirus type 5,
containing an AU-1 tagged dominant-negative version of FADD
(DFADD or NFD4), has been described elsewhere (28, 29). Adenovirus
carrying the lacZ gene, which expresses b-galactosidase protein, was
provided by Dr. J. Samulski (University of North Carolina, Chapel Hill)
and served as a control. The number of virions was confirmed as
described above for the AdFAK-CD virus.
Adenoviral Infections—Cells were plated at 1.5 3 106 per 100-mm
culture plates and allowed to attach for 24 h and then infected with
AdFAK-CD or AdlacZ for various time points at an optimal concentra-
tion of virus in complete media (Table I). Optimal concentrations of
virus were determined by infection of cells with the b-galactosidase-
expressing virus (AdlacZ) at different doses and subsequent staining
with 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal). We
used titers that caused expression of b-galactosidase in 100% of the cells
without visible toxic effect. For AdFAK-CD, cells were similarly trans-
duced with a range of viral concentrations. We typically infected cells
with 2 3 103 virions per cell and detected HA-tagged FAK-CD expres-
sion in greater than 90% of the cells using an anti-HA monoclonal
antibody (HA11, Babco, Richmond, CA) by fluorescence microscopy. For
co-infection experiments, cells were infected with AdFAK-CD or AdlacZ
together with DFADD adenoviruses at various virions per cell for 24 h.
Expression of FAK-CD or DFADD was verified by Western blotting
using anti-HA or anti-AU-1 (Babco) monoclonal antibodies.
Poly-HEMA-coated Tissue Culture Dishes and Suspension Cell Cul-
ture—Tissue culture dishes were coated with a film of poly-HEMA
(Aldrich) as described by Folkman and Moscona (30). Briefly, a 12%
solution of polyhydroxyethylmethacrylate polymer (poly-HEMA) in 95%
ethanol was mixed overnight, centrifuged at 2,500 rpm to remove un-
dissolved particles, and diluted 1:10 with 95% ethanol. 100-mm dishes
were coated with 4 ml of poly-HEMA solution and left to dry at room
temperature. Dishes were washed twice with PBS and once with HBSS
before use.
BT474 cells were typsinized, resuspended, and added to the poly-
HEMA coated dishes at a density of 1.5 3 106 per dish in serum-
containing medium. Cells were maintained in suspension culture for
various time points and assayed for proliferation, including growth
rate, BrdUrd incorporation, or cell survival, such as TUNEL and MTT
assay as described below.
For adenoviral infection of BT474 cells grown in suspension culture,
1.5 3 106 cells were added to poly-HEMA coated tissue culture dishes
and then immediately infected with AdFAK-CD or AdlacZ at a concen-
tration of 2 3 103 virions per cell and incubated for 24 h. For co-infection
experiments, cells were infected with AdFAK-CD or AdlacZ together
with various concentrations of adenovirus containing DFADD and in-
cubated for 24 h. Cells were then harvested and subjected to analyses.
Treatment with Caspase Inhibitors—A total of 1.5 3 106 BT474 cells
were plated on 100-mm uncoated tissue culture plates or plates coated
with poly-HEMA and treated with Ac-DEVD-CHO, Ac-YVAD-CHO
(Babco), or benzyloxycarbonyl-IETD-fluoromethyl ketone (Enzyme Sys-
tems Products, Livermore, CA) at various concentrations for 6 h. Cells
were subsequently infected with AdFAK-CD or AdlacZ for 24 h and
then harvested and assayed for apoptosis using the ApopTag kit (In-
tergen, Purchase, NY) as described below.
BrdUrd Labeling and Detection—Cells were maintained in suspen-
sion culture for 18, 42, or 66 h in serum-containing medium, and then
labeled with 30 mM BrdUrd (5-bromodeoxyuridine) for an additional 6 h.
Cells were then harvested and fixed in 70% ethanol for 30 min. Subse-
quently, cells were treated with 2 N HCl containing 0.5% Triton X-100
for 30 min at room temperature followed by 0.1 M Na2B4O7 for 5 min.
After washing with PBS, the cells were blocked with 0.5% bovine serum
albumin for 30 min at room temperature. Anti-BrdUrd monoclonal
antibody (Ab2, Calbiochem) was added at a concentration of 1 mg/ml to
the cells and incubated for 1 h followed by fluorescein isothiocyanate-
conjugated goat anti-mouse IgG. BrdUrd incorporation was determined
by the number of positive cells versus the number of total cells using a
Zeiss fluorescence microscope.
Assays of Cell Viability—Detection of apoptosis was performed by
TUNEL assay using the ApopTag kit (Intergen, Purchase, NY) accord-
ing to manufacturer’s protocol. Cell survival was assayed by measuring
mitochondrial dehydrogenase activity, conversion of soluble MTT into
an insoluble formazan product as described by Mosmant (31). Briefly,
BT474 cells grown in poly-HEMA-coated or uncoated tissue culture
dishes for 24 h were plated into a 96-well tissue culture plate at a
density of 2,500 cells per well in 100 ml of medium and allowed to attach
overnight at 37 °C. 10 ml of MTT solution (5 mg/ml in PBS, Sigma) was
added to each well and incubated for 1.5 h at 37 °C. The reaction was
stopped by removal of the supernatant followed by addition of 100 ml of
Me2SO. The plate was left at room temperature for 15 min with gently
rocking, and the absorbance at 595 nm was measured using a kinetic
microplate reader (Vmax, Molecular Devices). The percentage of survival
was calculated as cells grown in poly-HEMA experiment/cells grown in
monolayer culture 3 100.
Immunofluorescence, Western Blotting, and Immunoprecipitation—
Immunofluorescent staining for HA, p125FAK, or paxillin using the
anti-HA (HA11, Babco), anti-FAK, and anti-paxillin (Transduction Lab-
oratories) monoclonal antibodies has been described previously (24).
Tyrosine phosphorylation of p125FAK was analyzed by immunoprecipi-
tation using the anti-FAK 4.47 (Upstate Biotechnology, Inc.) mono-
clonal antibody or C20 (Santa Cruz Biotechnology) polyclonal antibody,
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followed by Western blotting with an anti-phosphotyrosine monoclonal
antibody (4G10, Upstate Biotechnology, Inc.) as described (24). The
expression of FAK-CD, p125FAK, vinculin, or poly-(ADP-ribose) polym-
erase (PARP) was analyzed by Western blot using the anti-HA (12CA5,
Roche Molecular Biochemicals), anti-FAK (C20, Santa Cruz Biotechnol-
ogy, or clone 77, Transduction Laboratories), anti-vinculin (Sigma), and
anti-PARP (Roche Molecular Biochemicals) antibodies.
RESULTS
Down-regulation of FAK Causes Loss of Cellular Adhesion
and Induces Apoptosis in Breast Cancer Cells—To interrupt
FAK signaling function, we generated an adenoviral FAK-CD
construct containing amino acids 693–1052 of the FAK protein,
fused in-frame at the amino-terminal end with a single copy of
the HA epitope tag. Human BT474 breast cancer cells were
infected with AdFAK-CD for 4, 8, 16, and 24 h. The expression
of FAK-CD was detected as early as 4 h post-infection and
reached the highest level between 8 and 24 h after infection
(Fig. 1A, top panel). By 16 h following infection, FAK-CD led to
loss of 125FAK expression (Fig. 1A, middle panel). This loss of
p125FAK expression was not due to a general degradation of
cellular proteins, because the focal adhesion protein vinculin
was stable throughout the experiment (Fig. 1A, bottom panel).
Preceding this loss of p125FAK expression, the level of p125FAK
tyrosine phosphorylation had dramatically decreased, and by
8 h, tyrosine-phosphorylated p125FAK was no longer detectable
(Fig. 1B).
The expression of FAK-CD was also analyzed by immunoflu-
orescence microscopy. Following 4 h of transduction, FAK-CD
expression was detected at the focal adhesions as well as the
cytoplasm (Fig. 2A). At 6 h some focal adhesion staining was
still visible, but by 8 h, the cells had become rounded (Fig. 2A).
By 16 h, greater than 90% of the cells expressing FAK-CD had
lost adhesion and become suspended.
To elucidate whether FAK-CD expression led to loss of en-
dogenous p125FAK from the focal adhesions, dual immunofluo-
rescence microscopy was performed to co-localize p125FAK and
FAK-CD, as well as p125FAK and paxillin. Before AdFAK-CD
was transduced, endogenous p125FAK was detected in focal
adhesions of BT474 cells, using an antibody to the kinase
domain of FAK that does not recognize FAK-CD (data not
shown). Following 6 h of transduction, p125FAK was no longer
detectable at the focal adhesions of the cells that expressed
FAK-CD (Fig. 2B, panels a and b). However, at this time point,
the focal adhesions were still intact as demonstrated by paxil-
lin staining (Fig. 2B, panels c and d). Cells infected with control
lacZ virus maintained p125FAK and paxillin expression at the
focal adhesions (Fig. 2B, panels e–h). These results demon-
strate that expression of FAK-CD was associated with loss of
the endogenous p125FAK from focal adhesions, resulting in a
loss of cellular adhesion.
To determine the fate of the detached cells, we analyzed
FIG. 1. Western blot analysis of FAK-CD expression and tyro-
sine phosphorylation of p125FAK in BT474 cells. A, expression of
FAK-CD, p125FAK, and vinculin following AdFAK-CD transduction in
BT474 cells. Human BT474 breast cancer cells were infected with
AdFAK-CD or a control lacZ adenovirus for 4, 8, 16, or 24 h and then
lysed in Nonidet P-40 buffer. The expression of FAK-CD, p125FAK, or
vinculin was analyzed by Western blot using an anti-HA (12CA5, Roche
Molecular Biochemicals) (top panel), anti-FAK (Transduction Labora-
tories), or anti-vinculin (Sigma) monoclonal antibodies. B, tyrosine
phosphorylation of p125FAK following AdFAK-CD transduction in
BT474 cells. Tyrosine phosphorylation and expression of p125FAK was
analyzed by immunoprecipitating (IP) p125FAK with the anti-FAK
monoclonal antibody (4.47, Upstate Biotechnology, Inc.) and then im-
munoblotting (IB) with either anti-phosphotyrosine antibody (4G10,
Upstate Biotechnology, Inc.) or the anti-FAK (4.47) antibody.
FIG. 2. Expression of FAK-CD in the breast tumor cells led to loss of endogenous p125FAK from the focal adhesions, cellular
rounding, and loss of adhesion. A, BT474 cells were infected with AdFAK-CD for 4, 6, or 8 h and analyzed for FAK-CD expression by
immunofluorescence microscopy using an anti-HA antibody. FAK-CD localized to the focal adhesions as well as the cytoplasm of the cells (panels
a and b). By 8 h, the cells had become rounded (panel c). B, BT474 cells were transduced with AdFAK-CD for 6 h, and dual immunofluorescence
microscopy was performed to co-localize endogenous p125FAK and FAK-CD, as well as p125FAK and paxillin, using the anti-HA (HA11, Babco),
anti-FAK kinase domain (clone 77, Transduction Laboratories), or anti-paxillin (clone 349, Transduction Laboratories) monoclonal antibodies.
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them for apoptosis by TUNEL assay 16 h after FAK-CD trans-
duction (Fig. 3A), and we showed an average of 86% of these
cells underwent apoptosis (Table I). Furthermore, we could not
detect the expression of endogenous p125FAK, but instead we
detected its degradation products of 85- (Fig. 3B, upper panel),
35-, and 23-kDa proteins (Fig. 3B, middle panel) as the cells
underwent apoptosis. We cannot exclude the possibility that
the two smaller proteins represent degradation of FAK-CD.
This is consistent with the observation of Wen et al. (32) that
p125FAK is degraded during apoptosis. In contrast, cells in-
fected with equivalent amounts of an adenovirus containing
the lacZ gene remained adherent to the tissue culture dish, and
these cells failed to show signs of apoptosis (Fig. 3A). To test
whether other breast cancer cell lines were sensitive to
FAK-CD induced apoptosis, we infected the MCF-7 breast can-
cer cell line and obtained similar results. More than 90% of the
cells lost adhesion, and 45% of these cells displayed morpho-
logical signs of apoptosis (Table I). Thus, the induction of loss of
adhesion and apoptosis by FAK-CD is not restricted to the
BT474 cell line.
FAK Function Has a Direct Effect on Tumor Cell Adhesion to
the ECM—Our initial experiments did not distinguish whether
interruption of FAK function disrupted adhesion, leading to
apoptosis, or whether FAK-CD directly induced apoptosis, with
subsequent loss of adhesion. To address this, BT474 cells were
pretreated with increasing doses of the peptide Ac-DEVD-
CHO, a caspase-3 inhibitor, and then infected with AdFAK-CD.
After 16 h of FAK-CD transduction, greater than 90% of cells
lost adhesion, but these cells did not undergo apoptosis (Fig.
4A, left panels) and the degradation of endogenous p125FAK
was inhibited in a dose-dependent fashion (Fig. 4B, middle
panel). In contrast, treating cells with a control peptide Ac-
YVAD-CHO, the interleukin-converting enzyme inhibitor, fol-
lowed by FAK-CD transduction did not block loss of adhesion,
apoptosis (Fig. 4A, right panels), or p125FAK degradation (Fig.
FIG. 3. Induction of apoptosis and degradation of p125FAK in
BT474 cells by FAK-CD. A, BT474 cells were infected with Ad-
FAK-CD or AdlacZ for 16 h, and apoptosis was detected by the TUNEL
assay using the ApopTag kit (Intergen). The percentage of apoptotic
cells was determined by counting a total of 100 cells in 3 random fields
(40 times) and dividing the number of apoptotic cells by the number of
total cells. B, BT474 cells were infected with AdFAK-CD or a control
lacZ adenovirus for 4, 8, or 24 h. The expression and degradation of
p125FAK were analyzed by Western blot using the anti-FAK kinase
domain monoclonal antibody (clone 77, Transduction Laboratories) (up-
per panel), anti-FAK COOH-terminal domain polyclonal antibody (C20,
Santa Cruz Biotechnology) (middle panel), or anti-HA (12CA5) mono-
clonal antibody (lower panel).
FIG. 4. Pretreatment of BT474 cells with caspase-3 inhibitor
followed by the transduction of AdFAK-CD blocked apoptosis
and p125FAK degradation. A, BT474 cells were treated with 50 mM
Ac-DEVD-CHO or Ac-YVAD-CHO for 6 h and then transduced with
AdFAK-CD or AdlacZ for 16 h. Apoptosis was analyzed by TUNEL
assay using the ApopTag kit. B, BT474 cells were treated with Ac-
DEVD-CHO (lanes 1–5) or Ac-YVAD-CHO peptide (lanes 6–10) at con-
centrations of 1 (lanes 1 and 6), 5 (lanes 2 and 7), 25 (lanes 3 and 8), or
50 (lanes 4, 5, 9, and 10) mM for 6 h and then transduced with Ad-
FAK-CD or AdlacZ for 16 h. Expression of FAK-CD or p125FAK was
analyzed by Western blot using an anti-HA monoclonal antibody
(12CA5, upper panel) or the anti-FAK polyclonal antibody (C20, middle
panel). The inhibition of caspase-3 was demonstrated by Western blot
using an anti-PARP polyclonal antibody (Roche Molecular Biochemi-
cals) (lower panels).
TABLE I
Induction of loss of adhesion and apoptosis by transduction
with Ad-FAK-CD
Cell line Virions/cell Loss of adhesiona Apoptosisb
%
BT474 2 3 103 99.3 6 1.6 86.1 6 5.3
MCF-7 1 3 104 92.7 6 2.3 45.0 6 2.4
MCF-10A 1 3 104 0.1 6 0.1 0
HME cells 1 3 104 1.1 6 0.5 0
a The percentage of loss of adhesion was determined by dividing the
number of detached cells versus the number of total cells following 24 h
of AdFAK-CD transduction. This result was observed using two differ-
ent preparations of adenovirus in more than three separate experi-
ments for each preparation. In contrast, cells treated with an adenovi-
rus containing the lacZ gene showed no significant loss of cellular
adhesion.
b Detection of apoptosis was performed by TUNEL assay. The per-
centage of apoptosis was determined by dividing the number of apo-
ptotic cells versus the number of total cells in ten 3 40 microscopic fields
with a fluorescence microscope. Data are presented as mean 6 S.D. of
three independent experiments.
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4B). Treatment of BT474 cells with the Ac-DEVD-CHO peptide
inhibited caspase-3 compared with cells treated with Ac-
YVAD-CHO (Fig. 4 B). A dose-dependent inhibition of
caspase-3 was also confirmed by a decrease in cleavage of a
caspase-3 substrate, PARP in treated cells (Fig. 4B, bottom
panel). This demonstrates that FAK-CD causes a loss of adhe-
sion and that subsequent p125FAK degradation and apoptosis
occur through a caspase-3-dependent mechanism. Therefore,
we propose that expression of FAK-CD caused loss of adhesion,
degradation of p125FAK, and finally caspase-3-dependent apo-
ptosis in tumor cells.
FAK Function Is Essential for the Survival of Breast Tumor
Cells Grown without Matrix Attachment—The above experi-
ments suggested that FAK prevented death in tumor cells by
aiding in adhesion to the cellular substratum. However, FAK
may also have a role as a survival signal that is independent of
adhesion. To test this hypothesis, BT474 cells were maintained
in poly-HEMA-coated tissue culture plates which allows for
anchorage-independent growth. These cells grew predomi-
nantly as a single cell suspension culture and remained viable
as determined by mitochondrial dehydrogenase activity using
the MTT assay (data not shown). In addition, these cells pro-
liferated (Fig. 5A) and incorporated BrdUrd (Fig. 5B) up to 72 h
after they were subjected to suspension culture. By 72 h reduc-
tion of BrdUrd uptake correlated with a reduced rate of cellular
growth. Surprisingly, p125FAK remained tyrosine-phosphory-
lated even in the absence of ECM signaling (Fig. 5D), suggest-
ing that these cells harbor a mechanism for constitutively
activating p125FAK that is independent of adhesion. However,
when BT474 cells grown in suspension were transduced with
AdFAK-CD, the endogenous p125FAK was degraded (Fig. 5, C
and D), and an average of 82% of these cells underwent apo-
ptosis after 24 h of infection. In contrast, cells infected with the
control adenovirus showed no detectable apoptosis. This result
demonstrates that FAK-CD does not induce apoptosis solely by
interrupting cellular adhesion and suggests that FAK plays an
additional role as a survival signal in tumor cells that is inde-
pendent of matrix signaling.
The Apoptotic Pathway Triggered by Down-regulation of FAK
Requires FADD and Caspase-8 Activation—Having shown that
expression of FAK-CD caused activation of caspase-3 and in-
duced apoptosis in BT474 cells, we wished to identify the up-
stream components that were involved in the apoptotic path-
way. One of these upstream molecules is caspase-8, an initiator
caspase, which has been implicated in diverse forms of apo-
ptosis (33). Thus, we examined caspase-8 activation in apop-
totic cells treated with AdFAK-CD. The expression of FAK-CD
resulted in a strong activation of caspase-8 as measured by
Western blotting using an antibody that detects the pro-form of
caspase-8 (Fig. 6B, 2nd and 7th lanes). To test whether
caspase-8 activation is required for FAK-CD-induced apoptosis,
cells were pretreated with increasing concentrations of a
caspase-8 specific inhibitor, benzyloxycarbonyl-IETD-fmk, for
6 h followed by infection with AdFAK-CD or control virus.
These results showed that inhibition of caspase-8 prevented
degradation of p125FAK (Fig. 6A, lower panel) and inhibited
FAK-CD-induced apoptosis in a dose-dependent manner (Fig.
6A, upper panel). Blockage of apoptosis by the caspase-8 inhib-
itor is independent of matrix adhesion, since the cells grown in
suspension resembled cells grown in monolayer culture (Fig.
6A).
Caspase-8 is thought to be recruited and activated by Fas-
associated death domain (FADD) protein in death receptor-
mediated apoptosis (34, 35), raising the possibility that
FAK-CD might trigger a FADD-dependent apoptotic pathway.
To test this, caspase-8 activation was blocked by expressing a
dominant-negative version of FADD (DFADD) that lacks the
death effector domain (amino acids 1–79) (28). AU1-tagged
DFADD was introduced into the cells by adenovirus transduc-
tion, and high levels of DFADD were detected in cells treated at
all concentrations of adenovirus (data not shown). Expression
of DFADD inhibited caspase-8 activation as demonstrated by
FIG. 5. Transduction of FAK-CD caused dephosphorylation and degradation of p125FAK in BT474 cells grown in suspension
culture. A, a total of 1.5 3 106 BT474 cells were added to 100-mm poly-HEMA-coated tissue culture dishes in medium containing 10% fetal bovine
serum. Cells were harvested and stained with trypan blue, and the trypan-blue exclusive cells were counted at 24, 48, or 72 h. B, BT474 cells were
grown in poly-HEMA-coated dishes in serum-containing medium for 18, 42, or 66 h and then labeled with BrdUrd for an additional 6 h. Cells were
then harvested, fixed, and stained with anti-BrdUrd monoclonal antibody (Ab2, Calbiochem) as described under “Experimental Procedures.”
BrdUrd-positive cells were counted and photographed using a Zeiss fluorescence microscope. C, 1.5 3 106 BT474 cells were added on 100-mm tissue
culture plates coated with poly-HEMA and then transduced with either AdlacZ control or with AdFAK-CD for 24 h. The expression of FAK-CD and
p125FAK was analyzed by Western blotting using an anti-HA (12CA5) or anti-FAK (Transduction Laboratories) monoclonal antibodies. D, 1.5 3 106
BT474 cells were added in poly-HEMA-coated tissue culture dishes and then left untreated or treated with AdFAK-CD or control lacZ adenovirus
for 24 h. Tyrosine phosphorylation and expression of p125FAK were analyzed by immunoprecipitating p125FAK with the anti-FAK polyclonal
antibody (C20) and then immunoblotting with either anti-phosphotyrosine antibody (4G10) or the anti-FAK antibody (C20).
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the presence of the pro-form enzyme (Fig. 6B, 3rd to 5th and
8th to 10th lanes) and prevented p125FAK degradation as well
(Fig. 6B). In addition, FAK-CD-induced apoptosis was signifi-
cantly blocked by DFADD even at a low concentration of ade-
novirus, both in monolayer and suspension cultures (Fig. 6B).
Taken together, these results show the importance of death
receptor-related death domain proteins in the apoptotic path-
way triggered by down-regulation of FAK.
Normal Mammary Epithelial Cells Are Resistant to Loss of
p125FAK Function—Since FAK function had a direct effect on
both the adhesion and survival of breast cancer cells, we next
compared the interruption of FAK function in breast cancer
cells and in normal mammary epithelial cells. In these exper-
iments, we treated human human mammary epithelial (HME)
cells with AdFAK-CD for 24 h. Following AdFAK-CD transduc-
tion, essentially all of the cells in the population expressed high
levels of FAK-CD protein by immunofluorescence and Western
blot with the anti-HA antibody (Fig. 7, A and B). Although
there was some focal adhesion staining for FAK-CD, there was
predominantly cytoplasmic staining in these cells (Fig. 7A,
panel a). Thus, we cannot determine whether FAK-CD has
directly caused loss of FAK from the focal adhesions or whether
some other mechanism is operative. Unlike the tumor cells,
however, the HME cells remained adherent, with no detectable
apoptosis. When these cells were trypsinized and replated,
approximately 60% were capable of readhering to the tissue
culture plates, with no difference between AdFAK-CD and
AdlacZ-treated cells (data not shown).
Furthermore, the endogenous p125FAK was no longer de-
tected at the focal adhesions (Fig. 7A, panels b and d) in
FAK-CD-treated cells as compared with lacZ-treated cells (Fig.
7A, panels f and h), in a manner similar to tumor cells, but
paxillin did remain at the focal adhesions (Fig. 7A, panel c).
Even though endogenous p125FAK was no longer localized to
the focal adhesions and its tyrosine phosphorylation was com-
pletely abrogated (Fig. 7B, middle panel), it did not become
degraded with expression of FAK-CD (Fig. 7B, bottom panel).
We also tested another normal mammary cell line, MCF-10A,
and found that expression of FAK-CD did not cause cellular
rounding, loss of adhesion, or apoptosis (Table I). Thus, under
these conditions, p125FAK was stable when removed from focal
adhesions in non-transformed cells, but was quickly degraded
in tumor cells.
DISCUSSION
These results suggest that in breast tumor cells, FAK has
two separate functions, one promoting the adhesive interac-
tions between tumor cells and their ECM, and the other acting
as a survival signal that is independent of cellular adhesion.
The effects of FAK-CD in BT474 cells were similar to anoikis (8,
10), whereby loss of adhesion was followed by a signal to
degrade p125FAK and to undergo apoptosis. However, this ef-
fect was not simply due to loss of matrix signals through the
interruption of FAK function by FAK-CD, as breast tumor cells
that were viable in suspension culture rapidly underwent ap-
optosis when transduced with FAK-CD. Additionally, this ef-
fect was not peculiar to BT474 cells since the different breast
tumor cell lines that we tested were highly sensitive to the loss
of adhesion induced by AdFAK-CD transduction but demon-
strated varying rates of apoptosis (data not shown).
These studies also suggest that degradation of p125FAK is
essential for tumor cells to undergo apoptosis. Inhibition of
caspase-3 prevented degradation of p125FAK and apoptosis but
did not have an effect on cellular adhesion. The degradation of
p125FAK in tumor cells by a caspase 3-based mechanism is in
agreement with other investigators who have shown that
p125FAK is cleaved by this cysteine protease (32, 36) as cells
undergo apoptosis. Furthermore, the blockage of apoptosis by
caspase-8 inhibition and by expression of DFADD strongly sug-
gests that a death receptor-induced signaling or death recep-
tor-related death domain proteins are involved in the apoptotic
process trigged by expression of FAK-CD. Activation of
caspase-8 has been shown to initiate a caspase cascade that
results in apoptosis through death receptor-mediated cell death
(37–39). In addition, other investigators have linked detach-
ment-induced apoptosis to FAK and caspase-8 (40, 41). How-
ever, our studies suggest the FAK signaling pathway is inhib-
iting death receptor-related apoptosis, independent of matrix
signaling.
In contrast, these studies demonstrate a different require-
FIG. 6. Inhibition of caspase-8 or ectopic expression of the
dominant-negative version of FADD (DFADD) blocked apopto-
sis and p125FAK degradation. A, inhibition of caspase-8 prevented
degradation of p125FAK and blocked apoptosis induced by expression of
FAK-CD. BT474 cells that were grown in monolayer or suspension
culture were pretreated with a specific caspase-8 inhibitor, benzyloxy-
carbonyl-IETD-fluoromethyl ketone, at a final concentration of 0, 1, 5,
10, or 20 mM for 6 h and subsequently infected with AdFAK-CD or
AdlacZ for 24 h in the presence of caspase-8 inhibitor. Apoptotic cells
were detected by TUNEL assay and quantitated as described above.
Expression and degradation of p125FAK were analyzed by Western
blotting using the anti-FAK (C20) polyclonal antibody (Santa Cruz
Biotechnology) (lower panel). B and C, ectopic expression of AU-1-
tagged dominant-negative version of FADD (DFADD) inhibited
caspase-8 activation and blocked apoptosis induced by FAK-CD. BT474
cells grown in monolayer or suspension culture were co-infected with
AdFAK-CD or AdlacZ together with adenovirus containing AU-1-
tagged DFADD at a concentration of 0, 200, 500, or 1000 virions per cell
for 24 h. B, the inhibition of caspase-8 and degradation p125FAK were
analyzed by Western blotting using the anti-proform of caspase-8 mono-
clonal antibody or anti-FAK (C20) polyclonal antibody (Santa Cruz
Biotechnology). C, apoptosis was demonstrated by TUNEL assay, and
the percentage of apoptosis was determined as described above.
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ment for FAK expression between breast cancer cells and nor-
mal mammary epithelial cells. Loss of p125FAK from focal ad-
hesions of normal breast epithelial cells resulted in the loss of
FAK tyrosine phosphorylation but did not cause loss of adhe-
sion or apoptosis, indicating that the function of FAK at the
focal adhesions was not essential for normal mammary epithe-
lial cell survival. It is unclear why down-regulation of FAK in
breast tumor cells leads to activation of a caspase cascade and
induces apoptosis, whereas down-regulation of FAK from nor-
mal mammary cells does not. We hypothesize that normal cells
have other ways of compensating for the loss of FAK function
caused by AdFAK-CD transduction, perhaps through other
kinases such as the FAK homologue, CADTK. This resistance
of normal cells to FAK down-regulation by FAK-CD is similar
to findings by Xiong and Parsons (42) and Ilic et al. (20).
However, these findings differ from those of Hungerford et al.
(43) who detected apoptosis following injection of anti-FAK
antibodies into chicken embryo fibroblasts. However, these in-
vestigators only detected apoptosis when cells were not fully
spread.
Our findings are consistent with those reported by Frisch et
al. (10) who showed that in Madin-Darby canine kidney cells,
expression of a constitutively active, membrane-bound form of
FAK was sufficient to transform the cells by anchorage-inde-
pendent growth criteria and tumor formation in nude mice. In
addition, the constitutively active FAK seen in breast tumor
cells grown in suspension is similar to the results of Renshaw
et al. (44) who showed that constitutively active FAK enhanced
the anchorage-independent growth of ras-transformed fibro-
blasts. Furthermore, our findings suggest that the function for
the high levels of FAK expressed in human tumor cells is to
suppress apoptosis, although the precise biochemical pathway
is not yet known. Richardson and et al. (45) have speculated
that FAK acts as a “switchable adapter,” bringing the Src
tyrosine kinase into close proximity to its substrate paxillin.
FAK-CD could bind to one or more of these carboxyl-terminal
partners that associate with the FAKzSrc complex, such as
paxillin, and disrupt the stoichiometry of the FAK signaling
complex. However, Src expression was not detectable in our
BT474 cells (data not shown), suggesting that FAK-CD may
disrupt other functions of FAK or be linked to other Src family
kinases, such as Fyn. In addition, the role of paxillin phospho-
rylation in the FAK-mediated survival signal, if any, is not
known. Indeed, our results suggest that the functions of FAK in
breast cancer cells may be distinct, with some promoting ad-
hesion and others acting as part of a survival signal pathway
for the suppression of apoptosis.
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